3.7. complicated utis. 3.7.1. introduction complicated uti (cuti) occurs individual factors related host (e.g. underlying diabetes immunosuppression) specific anatomical functional abnormalities related urinary tract (e.g. obstruction, incomplete voiding due detrusor muscle dysfunction) believed result infection difficult eradicate uncomplicated infection [230-232]. new insights management cutis also suggest consider infections caused multi-drug resistant uropathogens . underlying factors generally accepted result cuti outlined table 5. designation cuti encompasses wide variety underlying conditions result remarkably heterogeneous patient population. therefore, readily apparent universal approach evaluation treatment cutis sufficient, although general principles management applied majority patients cutis. following recommendations based stichting werkgroep antibioticabeleid (swab) guidelines dutch working party antibiotic policy . table 5: common factors associated complicated utis [233-236] obstruction site urinary tractuti malesforeign bodypregnancyincomplete voidingdiabetes mellitusvesicoureteral refluximmunosuppressionrecent history instrumentationhealthcare-associated infectionsisolated esbl-producing organismsisolated multi-drug resistant organisms 3.7.2. diagnostic evaluation 3.7.2.1. clinical presentation cuti associated clinical symptoms (e.g. dysuria, urgency, frequency, flank pain, costovertebral angle tenderness, suprapubic pain fever), although clinical situations symptoms may atypical example, nlutd, ca-uti patients undergone radical cystectomy urinary diversion. addition, patients nephrostomy may atypical clinical presentation. clinical presentation vary severe obstructive acute pyelonephritis imminent urosepsis post-operative ca-uti, might disappear spontaneously soon catheter removed. clinicians must also recognise symptoms, especially lower urinary tract symptoms (luts), caused utis also urological disorders, as, example, bladder outlet obstruction autonomic dysfunction patients spinal lesions nlutd. concomitant medical conditions, diabetes mellitus renal failure, related urological abnormalities, often also present cuti. 3.7.2.2. urine culture laboratory urine culture recommended method determine presence absence clinically significant bacteriuria patients suspected cuti. 3.7.3. microbiology (spectrum antimicrobial resistance) broad range micro-organisms cause cutis. spectrum much larger uncomplicated utis bacteria likely resistant (especially treatment-related cuti) isolated uncomplicated utis . e. coli, proteus spp., klebsiella spp., pseudomonas spp., serratia spp. enterococcus spp. common species found cultures. enterobacterales predominate (60-75%), e. coli common pathogen; particularly uti first infection. otherwise, bacterial spectrum may vary time one hospital another . 3.7.4. general principles cuti treatment appropriate management urological abnormality underlying complicating factor mandatory. optimal antimicrobial therapy cuti depends severity illness presentation, well local resistance patterns specific host factors (such allergies). addition, urine culture susceptibility testing performed, initial empirical therapy tailored followed (oral) administration appropriate antimicrobial agent basis isolated uropathogen. 3.7.4.1. choice antimicrobials considering current resistance percentages amoxicillin, co-amoxiclav, trimethoprim trimethoprim-sulphamethoxazole, concluded agents suitable empirical treatment pyelonephritis normal host and, therefore, also treatment cutis . applies ciprofloxacin fluoroquinolones urological patients . patients uti systemic symptoms requiring hospitalisation initially treated intravenous antimicrobial regimen, aminoglycoside without amoxicillin, second third generation cephalosporin, extended-spectrum penicillin without aminoglycoside . choice agents based local resistance data, regimen tailored basis susceptibility results . recommendations suitable pyelonephritis, cutis. alternative regimens treatment cutis, particularly caused multidrug-resistant pathogens studied. ceftolozane/tazobactam 1.5 g every eight hours demonstrated high clinical cure rates cutis caused esbl-producing enterobacterales pooled analysis phase 3 clinical trials . cefiderocol (2 g) three times daily non-inferior imipenem-cilastatin (1 g) three times daily treatment cuti patients multidrug-resistant gram-negative infections . imipenem/cilastatin plus relebactam (250 125 mg) effective imipenem/cilastatin alone treatment cuti phase 2 rct . ceftazidime/avibactam shown effective carbapenems treatment cuti systematic review reporting baseline 25% esbl-producing enterobacterales, severe adverse events reported ceftazidime/avibactam group . once-daily plazomicin shown non-inferior meropenem treatment cutis caused enterobacterales, including multidrug-resistant strains . view high degree resistance, particularly among patients admitted department urology, fluoroquinolones automatically suitable empirical antimicrobial therapy, especially patient used ciprofloxacin last six months . fluoroquinolones recommended empirical treatment patient seriously ill considered safe start initial oral treatment patient anaphylactic reaction beta-lactam antimicrobials. intravenous levofloxacin 750 mg daily five days shown non-inferior seven fourteen days regimen levofloxacin 500 mg daily starting intravenously switched oral regimen (based mitigation clinical symptoms) . 3.7.4.2. duration antimicrobial therapy treatment seven fourteen days (for men fourteen days prostatitis cannot excluded) , generally recommended, duration closely related treatment underlying abnormality. patient hemodynamically stable afebrile least 48 hours, shorter treatment duration (e.g. seven days) may considered patients short-course treatment desired due relative-contraindications administered antibiotic . 3.7.5. summary evidence recommendations treatment complicated utis summary evidencelepatients uti systemic symptoms requiring hospitalisation initially treated intravenous antimicrobial regimen chosen based local resistance data previous urine culture results patient, available. regimen tailored basis susceptibility result.1bif prevalence fluoroquinolone resistance thought < 10% patient contraindications third generation cephalosporins aminoglycoside, ciprofloxacin prescribed empirical treatment women complicated pyelonephritis.2in event hypersensitivity penicillin cephalosporins still prescribed, unless patient systemic anaphylaxis past.2in patients cuti systemic symptoms, empirical treatment cover esbl increased likelihood esbl infection based prevalence community, earlier collected cultures prior antimicrobial exposure patient.2intravenous levofloxacin 750 mg daily five days, non-inferior seven fourteen day regimen levofloxacin 500 mg daily starting intravenously switched oral regimen (based mitigation clinical symptoms).2 recommendationsstrength ratinguse combination of:amoxicillin plus aminoglycoside;a second-generation cephalosporin plus aminoglycoside;a third-generation cephalosporin intravenously empirical treatment complicated uti systemic symptoms.strongonly use ciprofloxacin provided local resistance percentages < 10% when;the entire treatment given orally;patients require hospitalisation;patient anaphylaxis beta-lactam antimicrobials.strongdo use ciprofloxacin fluoroquinolones empirical treatment complicated uti patients urology departments patients used fluoroquinolones last six months.strongmanage urological abnormality and/or underlying complicating factors.strong